TY - JOUR
T1 - Indication for resection and possibility of observation for intraductal papillary mucinous neoplasm with high-risk stigmata
AU - Abe, Kodai
AU - Kitago, Minoru
AU - Masugi, Yohei
AU - Iwasaki, Eisuke
AU - Yagi, Hiroshi
AU - Abe, Yuta
AU - Hasegawa, Yasushi
AU - Fukuhara, Seiichiro
AU - Hori, Shutaro
AU - Tanaka, Masayuki
AU - Nakano, Yutaka
AU - Yokose, Takahiro
AU - Shimane, Gaku
AU - Sakamoto, Michiie
AU - Kitagawa, Yuko
N1 - Publisher Copyright:
© 2021 IAP and EPC
PY - 2021/6
Y1 - 2021/6
N2 - Background/Objectives: According to the revised international intraductal papillary mucinous neoplasm (IPMN) guidelines (2017), the indication for surgery is based on risk classification. However, some IPMNs with high-risk stigmata (HRS) can be observed for long periods without resection. Hence, we need to reconsider the risk stratification, and this study aimed to propose a novel risk stratification for HRS-IPMNs. Methods: We enrolled 328 patients diagnosed with IPMN using endoscopic ultrasound between 2012 and 2019. We compared clinicopathological features between HRS and worrisome features (WF) and evaluated outcomes of HRS-IPMN. Results: Fifty-three patients (HRS 38, WF 15) underwent resection at initial diagnosis and 275 patients were observed. Following observation for 30 months, 22 patients (17 HRS, 5 WF) underwent resection. Analysis of resected IPMNs (n = 75) revealed that HRS had dominantly pancreatobiliary mucin subtype. Pancreatobiliary-type IPMN had larger nodule sizes and lymphatic invasion and high recurrence with poor prognosis. Seventy-four patients were diagnosed with HRS, 55 underwent resection, and 19 continue to be observed. The resected group had larger nodule sizes (median 8 mm vs. 5 mm; P = 0.060), whereas the observed group had more main pancreatic duct (MPD) dilation (median 10 mm vs. 5 mm; P = 0.005). In the resected HRS group, only patients with MPD dilation ≥10 mm (n = 10) had no recurrence but had a favorable prognosis compared with those nodule size ≥5 mm (n = 45). Conclusions: Large nodule size may be associated with pancreatobiliary subtype and poor prognosis; however, patients with MPD dilation ≥10 mm with nodule size <5 mm did not require resection.
AB - Background/Objectives: According to the revised international intraductal papillary mucinous neoplasm (IPMN) guidelines (2017), the indication for surgery is based on risk classification. However, some IPMNs with high-risk stigmata (HRS) can be observed for long periods without resection. Hence, we need to reconsider the risk stratification, and this study aimed to propose a novel risk stratification for HRS-IPMNs. Methods: We enrolled 328 patients diagnosed with IPMN using endoscopic ultrasound between 2012 and 2019. We compared clinicopathological features between HRS and worrisome features (WF) and evaluated outcomes of HRS-IPMN. Results: Fifty-three patients (HRS 38, WF 15) underwent resection at initial diagnosis and 275 patients were observed. Following observation for 30 months, 22 patients (17 HRS, 5 WF) underwent resection. Analysis of resected IPMNs (n = 75) revealed that HRS had dominantly pancreatobiliary mucin subtype. Pancreatobiliary-type IPMN had larger nodule sizes and lymphatic invasion and high recurrence with poor prognosis. Seventy-four patients were diagnosed with HRS, 55 underwent resection, and 19 continue to be observed. The resected group had larger nodule sizes (median 8 mm vs. 5 mm; P = 0.060), whereas the observed group had more main pancreatic duct (MPD) dilation (median 10 mm vs. 5 mm; P = 0.005). In the resected HRS group, only patients with MPD dilation ≥10 mm (n = 10) had no recurrence but had a favorable prognosis compared with those nodule size ≥5 mm (n = 45). Conclusions: Large nodule size may be associated with pancreatobiliary subtype and poor prognosis; however, patients with MPD dilation ≥10 mm with nodule size <5 mm did not require resection.
KW - High-risk stigmata
KW - IPMN
KW - Main pancreatic duct
KW - Pancreatobiliary subtype
UR - http://www.scopus.com/inward/record.url?scp=85101368499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101368499&partnerID=8YFLogxK
U2 - 10.1016/j.pan.2021.02.012
DO - 10.1016/j.pan.2021.02.012
M3 - Article
C2 - 33632666
AN - SCOPUS:85101368499
SN - 1424-3903
VL - 21
SP - 755
EP - 762
JO - Pancreatology
JF - Pancreatology
IS - 4
ER -